{"entity":{"id":"nct03600441","kind":"trial","name":"Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma","aka":["FORERUNNER"],"tldr":"A phase 2 trial of Abexinostat in follicular lymphoma, run by Xynomic Pharmaceuticals, Inc., active and no longer recruiting.","summary":"Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma is a phase 2 interventional study registered as NCT03600441 by Xynomic Pharmaceuticals, Inc., with 139 participants planned, started 2018-08-27 and due to reach its primary completion in 2027-12-31. Interventions recorded: Abexinostat. Conditions listed: Follicular Lymphoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03600441","url":"https://clinicaltrials.gov/study/NCT03600441"}],"tags":["ctgov-ingest"],"related":[],"cancers":["follicular-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["abexinostat"],"companies":["xynomic-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03600441","phase":"2","setting":"Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)","sponsor":"Xynomic Pharmaceuticals, Inc.","started":"2018-08-27","startedType":"actual","enrolled":139,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03600441/","neighbours":{"cancer":[{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"}],"drug":[{"id":"abexinostat","kind":"drug","name":"Abexinostat","route":"/drugs/abexinostat/"}],"company":[{"id":"xynomic-pharmaceuticals","kind":"company","name":"Xynomic Pharmaceuticals","route":"/companies/xynomic-pharmaceuticals/"}]}}